REGN

Regeneron is expected to report Q3 2026 earnings of $16.08 per share (up 35.9% YoY) and revenues of $4.55 billion (up 21.2% YoY) on October 30. However, the company's Earnings ESP is -1.12%, indicating recent analyst bearishness, making it difficult to predict an earnings beat despite its Zacks Rank #3 rating. The company has a strong history of beating estimates, having surpassed consensus four times in the last four quarters.

Regeneron Pharmaceuticals is emerging as a competitive player in the rapidly growing weight loss market with two differentiated candidates: olatorepatide, which shows better gastrointestinal tolerability than competitors with 19% mean weight loss, and trevogrumab, designed to preserve lean muscle mass alongside anti-obesity drugs. Beyond weight loss, Regeneron's strong pipeline including Dupixent and newer Eylea HD formulation positions it for medium-term growth.

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could potentially beat their quarterly earnings estimates. Regeneron (REGN) holds a #3 (Hold) rating with a +0.23% ESP ahead of its October 30, 2026 earnings release, while Danaher (DHR) has a #2 (Buy) rating with a +0.30% ESP before reporting on October 21, 2026. Both stocks show indicators suggesting potential positive earnings surprises.

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could beat their upcoming quarterly earnings estimates. ANI Pharmaceuticals (ANIP) has a +6.45% ESP ahead of its November 6, 2026 earnings release, while Regeneron (REGN) has a +0.23% ESP before reporting on October 30, 2026. Both stocks carry a Zacks Rank #3 (Hold) rating, and the article suggests that stocks with positive ESP combined with a Zacks Rank #3 or better have historically beaten earnings 70% of the time.

Regeneron (REGN) is positioned to potentially beat earnings estimates in its upcoming October 30, 2026 report. The company has a strong track record of beating estimates with an average surprise of 27.03% over the past two quarters, most recently delivering a 42.90% surprise. With a positive Earnings ESP of +1.21% and a Zacks Rank #3 (Hold), the combination suggests a high probability of another earnings beat.

Regeneron (REGN), a biotechnology company focused on severe medical conditions, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The company features attractive valuation metrics with a forward P/E ratio of 13.47, and two analysts revised earnings estimates higher in the last 60 days, with the consensus estimate increasing to $54.90 per share for fiscal 2026.

A comparison of two Medical-Biomedical and Genetics stocks reveals that Regeneron (REGN) presents a better value opportunity than Illumina (ILMN) for value investors. REGN has a stronger Zacks Rank of #1 (Strong Buy) versus ILMN's #2 (Buy), along with significantly more attractive valuation metrics including a forward P/E of 14.16 versus ILMN's 50.77, and a PEG ratio of 1.23 versus 3.85.

Regeneron Pharmaceuticals stock has underperformed this year, down around 1%, but the company demonstrated strong fundamentals in its last earnings report with 17% revenue growth and impressive drug sales. With a modest valuation (19x trailing earnings vs. S&P 500's 23x), a robust pipeline of 50 product candidates, and upcoming Q3 earnings on Oct. 30, analysts suggest the stock could be poised for a rally and represents a solid value buy for long-term investors.

A Motley Fool podcast discusses how historical S-1 risk factors from Amazon, Alphabet, and Meta didn't materialize into existential threats, offering perspective on Anthropic's alarming AI risks. The hosts identify stocks hitting new lows amid market fear—including Brookfield Corporation, Shopify, and Realty Income—while explaining how rising bond yields create both challenges for growth stocks and opportunities for cash-rich businesses and financial institutions.

Despite declining Eylea sales, Regeneron's strong performance is driven by Dupixent, a blockbuster drug developed with Sanofi that generated $6 billion in global sales with 38% year-over-year growth. The company's Q2 revenue grew 17% to $4.3 billion, with Dupixent collaboration revenue jumping 51%. While Dupixent faces biosimilar competition in the early 2030s, Regeneron plans to defend its market position through improved formulations, pipeline replacements, and promising candidates like olatorepatide in the weight-loss market.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all approved cancer indications. The new regimen allows for extended dosing of 700 mg every six weeks after an initial 12-week treatment with 350 mg every three weeks, and optional reduction of infusion time to 15-30 minutes. The European Commission is expected to make a final decision in the coming months.

Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027.

Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating.

EyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating.

Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook.

Bayer announced FDA acceptance of a supplemental new drug application for Kerendia (finerenone) to treat chronic kidney disease in non-diabetic patients. The approval is based on positive phase III FIND-CKD trial data showing the drug significantly delayed kidney disease progression and reduced cardiovascular-kidney events. This expansion broadens Kerendia's addressable market and strengthens Bayer's cardiovascular and renal portfolio, with the drug already approved for diabetic CKD and heart failure in multiple markets.

Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.

Regeneron announced presentations of new clinical research at ESMO Congress 2026, highlighting late-breaking Phase 3 data for Libtayo (cemiplimab) in cutaneous squamous cell carcinoma, Phase 2 neoadjuvant treatment data, and new research on Factor XI antibodies for cancer-associated thrombosis. The company is presenting 10 abstracts covering trials in CSCC, NSCLC, ovarian cancer, melanoma, and cancer-associated thrombosis.

Sanofi announced the availability of its Q3 2026 results aide-mémoire on October 6, 2026, with full results to be published on October 30, 2026. The company also announced expansions of strategic partnerships with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines.

Sanofi announced the publication of its Q3 2026 aide-mémoire on October 6, 2026, with full quarterly results to follow on October 30, 2026. The company also announced expansions of strategic alliances with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines partnerships.

Sanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030.